Semaglutide has more human trial data behind it than every other compound on this site combined — ten completed Phase 3 trials, an FDA approval, and a cardiovascular-outcomes trial on top of that. It's also the compound where the line between "what the evidence supports" and "what's actually in the vial" matters most. This guide keeps those two facts separate on purpose.
What Is Semaglutide?
Semaglutide is a modified version of human GLP-1 (94% sequence homology) engineered to resist the enzyme, DPP-4, that normally breaks native GLP-1 down within minutes. That structural change is what turns a hormone with a half-life under two minutes into a once-weekly injection.
Mechanism of Action
Semaglutide acts on three separate physiological systems, and each contributes differently to the weight-loss result:
- Pancreas — glucose-dependent insulin release. GLP-1 receptor activation on pancreatic beta cells amplifies insulin secretion, but only when blood glucose is already elevated. This "glucose-dependent" qualifier is why the drug carries a comparatively low hypoglycemia risk on its own.
- Stomach — delayed gastric emptying. Slower stomach emptying extends the feeling of fullness after a meal and blunts the post-meal blood sugar spike.
- Brain — appetite suppression via the vagus nerve and hypothalamus. This does most of the weight-loss work. GLP-1 signals reach appetite-control centers largely through vagal afferent neurons carrying signals from the gut to the brainstem, with further modulation of hypothalamic neurons involved in hunger and food reward.
In plain terms: semaglutide doesn't burn fat directly. It reduces how much food you want to eat and how quickly your body processes each meal — the weight loss is a downstream consequence of reduced intake, which is also why the STEP trials paired it with behavioral and dietary counseling rather than testing the drug in isolation.
Human Evidence
This is the strongest evidence base of any compound on the site. The STEP trial program — ten completed Phase 3 randomized controlled trials plus a teen trial — is the basis for FDA approval of Wegovy (2.4 mg/week) for chronic weight management:
- STEP 1 (obesity/overweight, no diabetes, 68 weeks): −14.9% body weight vs. −2.4% for placebo.
- STEP 3 (added intensive behavioral therapy, 68 weeks): −16.0% vs. −5.7% for placebo.
- STEP 5 (long-term maintenance, 2 years): −15.2% vs. −2.6% for placebo.
- STEP 8 (head-to-head vs. liraglutide): −15.8% for semaglutide; both semaglutide and liraglutide outperformed placebo.
STEP 1's extension found that weight regain resumed after stopping the drug — participants gained back a majority of the lost weight by 120 weeks. That's directly relevant to anyone expecting a "cycle on, cycle off" research protocol to hold results.
The Line Between the Approved Drug and What's Sold as "Research" Semaglutide
This is the compliance-relevant distinction. The evidence above is for FDA-approved Ozempic and Wegovy — specific manufactured pharmaceutical products. What research-peptide vendors sell as "semaglutide" is compounded material, and FDA has specifically warned that some compounded products use salt forms — semaglutide sodium or semaglutide acetate — which are chemically different active ingredients than the approved drug, with no evidence they're equivalent. FDA also documented patients self-administering 5–20x the intended dose due to compounded-product measuring errors, and issued 25 warning letters to telehealth companies over false or misleading compounded-GLP-1 marketing.
The STEP trials are real evidence for the molecule's mechanism and effect — but they were conducted with the approved pharmaceutical product, not a compounded research-vial version. The two are not established as equivalent, and nothing on this page should be read as a claim that they are.
Where to Source Semaglutide for Research
For legitimate research applications, purity and accurate dosing are critical. We only list vendors who provide third-party HPLC testing and batch-specific Certificates of Analysis.
View the Semaglutide product page →Frequently Asked Questions
Is the semaglutide sold by research vendors the same as Ozempic or Wegovy?
No. Ozempic and Wegovy are specific FDA-approved manufactured products. Semaglutide sold for research use is compounded material, sometimes in a different salt form, and has not been established as equivalent to the approved drug.
Does the weight loss last after stopping semaglutide?
The STEP 1 trial extension found that most participants regained a majority of the lost weight within about a year of stopping the drug — the effect appears to require continued use, not a one-time reset.
References
1. Semaglutide, Mechanism of Action. StatPearls / NCBI Bookshelf. ncbi.nlm.nih.gov
2. Chao AM, et al. "Semaglutide for the treatment of overweight and obesity: A review." PMC. pmc.ncbi.nlm.nih.gov
3. FDA. "FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss." fda.gov
4. Reuters. "US FDA warns online vendors selling unapproved weight-loss drugs," Dec 2024. reuters.com
5. Schirra J, Göke B. "The physiological role of GLP-1 in human: incretin, ileal brake or what?" PubMed, 2005. pubmed.ncbi.nlm.nih.gov
6. Moiz A, et al. "Mechanisms of GLP-1 Receptor Agonist-Induced Weight Loss," 2025. sciencedirect.com
This article contains affiliate links. Aura Protocols may earn a commission if you purchase through these links at no additional cost to you. All compounds are for research use only.